Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. Its lead product candidate, Elraglusib Injection, is a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. The company also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. It has license agreements with the University of Illinois-Chicago and Northwestern University for the use of GSK-3B inhibitor. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is based in Fort Worth, Texas.